Concluding Remarks

  • Domenico Ribatti


Starting with the hypothesis of Judah Folkman that tumor growth is angiogenesis dependent, this area of research now has a solid scientific foundation. In 2008, Robert Kerbel dedicated a review article published in the “New England Journal of Medicine” to the memory of Judah Folkman: “mentor, friend, and colleague, whose visionary hypothesis and numerous pioneering discoveries opened up and advanced the field of tumor angiogenesis and anti-angiogenic therapy.


  1. Allen E, Walters IB, Hanahan D (2011) Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 17:5299–5310CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bergers G, Song S, Mayer-Morse N et al (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287–1295CrossRefPubMedPubMedCentralGoogle Scholar
  3. Ferrara N, Kerbel R (2005) Angiogenesis as a therapeutic target. Nature 438:967–974CrossRefPubMedGoogle Scholar
  4. Folkman J (2006a) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312:594–607CrossRefPubMedGoogle Scholar
  5. Folkman J (2006b) Angiogenesis. Annu Rev Med 57:1–18CrossRefPubMedGoogle Scholar
  6. Franco M, Paez-Ribes M, Cortez E et al (2011) Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy. Horm Metab Res 43:884–889CrossRefPubMedGoogle Scholar
  7. Goel S, Duda DG, Xu L et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071–1121CrossRefPubMedPubMedCentralGoogle Scholar
  8. Jin K, Lan H, Cao F et al (2012) Differential response to EGFR- and VEGFR-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. Int J Oncol 41:583–588CrossRefPubMedGoogle Scholar
  9. Kerbel RS (2008) Tumor angiogenesis. New Engl J Med 358:2039–2049CrossRefPubMedGoogle Scholar
  10. Kopetz S, Hoff PM, Morris JS et al (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453–459CrossRefPubMedGoogle Scholar
  11. Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610–2621CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Domenico Ribatti
    • 1
  1. 1.Department of Basic Medical Sciences, Neurosciences and Sensory OrgansUniversity of Bari Medical SchoolBariItaly

Personalised recommendations